Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes.
This paper addresses treatment effect heterogeneity (also referred to, more compactly, as 'treatment heterogeneity') in the context of a controlled clinical trial with binary endpoints. Treatment heterogeneity, variation in the true (causal) individual treatment effects, is explored using the concept of the potential outcome. This framework supposes the existance of latent responses for each subject corresponding to each possible treatment. In the context of a binary endpoint, treatment heterogeniety may be represented by the parameter, pi2, the probability that an individual would have a failure on the experimental treatment, if received, and would have a success on control, if received. Previous research derived bounds for pi2 based on matched pairs data. The present research extends this method to the blocked data context. Estimates (and their variances) and confidence intervals for the bounds are derived. We apply the new method to data from a renal disease clinical trial. In this example, bounds based on the blocked data are narrower than the corresponding bounds based only on the marginal success proportions. Some remaining challenges (including the possibility of further reducing bound widths) are discussed.
Albert
Jeffrey M
JM
Department of Epidemiology and Biostatistics, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA. jma13@case.edu
Gadbury
Gary L
GL
Mascha
Edward J
EJ
D000704:Analysis of Variance; D015984:Causality; D004044:Dietary Proteins / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000178:diet therapy; D007677:Kidney Function Tests / Q000706:statistics & numerical data; D015337:Multicenter Studies as Topic / Q000379:methods / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data*; D017211:Treatment Failure; D016896:Treatment Outcome
D004044:Dietary Proteins